We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 585334

CAS#: 112984-60-8

Description: Ulifloxacin is a quinolone antibiotic and effective against pneumonia.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

Ulifloxacin is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 585334
Name: Ulifloxacin
CAS#: 112984-60-8
Chemical Formula: C16H16FN3O3S
Exact Mass: 349.0896
Molecular Weight: 349.3804
Elemental Analysis: C, 55.00; H, 4.62; F, 5.44; N, 12.03; O, 13.74; S, 9.18

Synonym: Ulifloxacin; NM-394; NM394; NM 394

IUPAC/Chemical Name: 6-fluoro-1-methyl-4-oxo-7-piperazin-1-yl-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid


InChi Code: InChI=1S/C16H16FN3O3S/c1-8-20-11-7-12(19-4-2-18-3-5-19)10(17)6-9(11)14(21)13(16(22)23)15(20)24-8/h6-8,18H,2-5H2,1H3,(H,22,23)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Keam SJ, Perry CM. Prulifloxacin. Drugs. 2004;64(19):2221-34; discussion 2235-6. PubMed PMID: 15456336.

2: Montanari MP, Ferrante L, Tili E, Cochetti I, Rossi V, Varaldo PE. Interpretive criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin. J Chemother. 2005 Apr;17(2):138-42. PubMed PMID: 15920898.

3: Passali D, Crisanti A, Bellussi LM. Role of prulifloxacin in the treatment of acute rhinosinusitis. Infez Med. 2015 Dec;23(4):301-6. Review. PubMed PMID: 26700078.

4: Tellone V, Coppola P, Ammendola M, Di Loreto G, Picollo R, Del Vecchio A, Comandini A, Garofolo F, Tongiani S. New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment. Drugs R D. 2018 Sep;18(3):237-245. doi: 10.1007/s40268-018-0245-9. PubMed PMID: 30151791; PubMed Central PMCID: PMC6131124.

5: Tascini C, Mantengoli E, Geminiani G, Leonildi A, Di Maggio T, Fondelli S, Rossolini GM, Tagiaferri E, Menichetti F. [In vitro synergism of ulifloxacin plus piperacillin/tazobactam against clinical isolates of Enterobacteriaceae producing extended-spectrum or AmpC-type β-lactamases]. Infez Med. 2010 Dec;18(4):243-7. Italian. PubMed PMID: 21196818.

6: Aoki M, Iguchi M, Hayashi H, Shibasaki S, Kurosawa T, Hayashi M. Active uptake of ulifloxacin from plasma to lung that controls its concentration in epithelial lining fluid. Biol Pharm Bull. 2009 Jun;32(6):1095-100. PubMed PMID: 19483322.

7: Karageorgopoulos DE, Maraki S, Vatopoulos AC, Samonis G, Schito GC, Falagas ME. Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece. Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1417-22. doi: 10.1007/s10096-013-1891-z. Epub 2013 May 19. PubMed PMID: 23686506.

8: Locatelli M, Cifelli R, Carlucci G, Romagnoli A. Stability study of Prulifloxacin and Ulifloxacin in human plasma by HPLC-DAD. J Enzyme Inhib Med Chem. 2016;31(1):106-11. doi: 10.3109/14756366.2015.1004062. Epub 2015 Feb 16. PubMed PMID: 25683081.

9: Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther. 2006;19 Suppl 1:20-9. Epub 2005 Dec 19. Review. PubMed PMID: 16360331.

10: Nandi U, Roy B, Das AK, Pal TK. Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats. Environ Toxicol Pharmacol. 2012 Sep;34(2):588-607. doi: 10.1016/j.etap.2012.07.001. Epub 2012 Jul 14. PubMed PMID: 22885677.

11: Ferrone V, Carlucci M, Palumbo P, Carlucci G. Bioanalytical method development for quantification of ulifloxacin, fenbufen and felbinac in rat plasma by solid-phase extraction (SPE) and HPLC with PDA detection. J Pharm Biomed Anal. 2016 May 10;123:205-12. doi: 10.1016/j.jpba.2016.01.062. Epub 2016 Feb 1. PubMed PMID: 26898973.

12: Giberti C, Gallo F, Rosignoli MT, Ruggieri A, Barattè S, Picollo R, Dionisio P. Penetration of orally administered prulifloxacin into human prostate tissue. Clin Drug Investig. 2009;29(1):27-34. doi: 10.2165/0044011-200929010-00003. PubMed PMID: 19067472.

13: Roy B, Choudhury H, Das A, Das AK, Pal TK. Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: application to toxicokinetic study. Biomed Chromatogr. 2011 Aug;25(8):890-901. doi: 10.1002/bmc.1539. Epub 2010 Dec 10. PubMed PMID: 21154639.

14: Ferrone V, Carlucci M, Palumbo P, Carlucci G. Development and validation of a MEPS-UHPLC-PDA method for determination of ulifloxacin in human plasma and urine of patients with peripheral arterial disease. J Pharm Biomed Anal. 2016 Sep 5;128:313-321. doi: 10.1016/j.jpba.2016.06.001. Epub 2016 Jun 4. PubMed PMID: 27318081.

15: Concia E, Allegranzi B, Ciottoli GB, Orticelli G, Marchetti M, Dionisio P. Penetration of orally administered prulifloxacin into human lung tissue. Clin Pharmacokinet. 2005;44(12):1287-94. PubMed PMID: 16372826.

16: Zhang L, Wen J, Pan Y, Li Z, Fan G, Wu Y. Determination of ulifloxacin, the active metabolite of prulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 1;872(1-2):172-6. doi: 10.1016/j.jchromb.2008.07.033. Epub 2008 Aug 5. PubMed PMID: 18706872.

17: Dong P, Xu N, Fu B, Wang L. Rapid europium-sensitized fluorescent determination of ulifloxacin, the active metabolite of prulifloxacin, in human serum and urine. J Pharm Anal. 2011 Feb;1(1):46-50. doi: 10.1016/S2095-1779(11)70008-9. Epub 2012 Jan 30. PubMed PMID: 29403681; PubMed Central PMCID: PMC5760754.

18: Yagi Y, Aoki M, Iguchi M, Shibasaki S, Kurosawa T, Kato Y, Tsuji A. Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats. Drug Metab Pharmacokinet. 2007 Oct;22(5):350-7. PubMed PMID: 17965518.

19: Aoki M, Iguchi M, Hayashi H, Suzuki H, Shibasaki S, Kurosawa T, Hayashi M. Proposal of membrane transport mechanism of protein-unbound ulifloxacin into epithelial lining fluid determined by improved microdialysis. Biol Pharm Bull. 2008 Sep;31(9):1773-7. PubMed PMID: 18758075.

20: Wang X, Shen B, Zhao H, Jin L. Determination of ulifloxacin by terbium-sensitized fluorescence with second-order scattering and its applications. Anal Sci. 2007 Dec;23(12):1373-6. PubMed PMID: 18071221.